News round-up for 3-7 June by DDW Senior Digital Content Editor Diana Spencer. With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event. The top stories:… Read More
Pheon Therapeutics has completed a $120m Series B financing to fund the development of its pipeline of next generation ADCs for a wide range of hard-to-treat cancers. The new financing will be used to further advance Pheon’s differentiated ADC pipeline through clinical proof of concept. The first three… Read More
Deepika Khedekar, Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. Ten million1 people around the world die from cancer each year. Yet, while the number of cancer clinical trials has soared from 19,211… Read More
A US study suggests Novo Nordisk’s GLP-1 receptor agonist Ozempic (semaglutide), which is approved as a treatment for diabetes and weight loss (as Wegovy), could reduce the risk of cancer. Ozempic has been in the spotlight recently following study data proving that patients taking it had… Read More
DDW’s Megan Thomas talks to Dr Henrik Jespersen, Head of Melanoma Oncology, at Oslo University Hospital. MT: Where do you work, and can you tell us what you’re working on at the moment? HJ: I work as a clinical oncologist at Oslo University Hospital where I am head of… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. A leading news story this week has been the announcement of positive Phase II… Read More
News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More
Lantern Pharma has entered a strategic AI-driven collaboration with French biotechnology company Oregon Therapeutics to optimise the development of its first-in-class protein disulfide isomerase (PDI)1 inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its RADR AI platform to uncover biomarkers and… Read More
Calliditas Therapeutics has announced data from the proof-of-concept Phase II trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN). The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Steve Worland,… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The leading news story this week has been the launch of a new clinical… Read More
News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer. The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in… Read More
This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Going paperless – the move to electronic lab… Read More
Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The cancer research news has been coming thick and fast from the American Association… Read More
News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer. The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology. Read More
